No Cover Image

Journal article 182 views 25 downloads

Association of British Clinical Diabetologists and UK Kidney Association joint clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD

Janaka Karalliedde, Kieran McCafferty, Peter Winocour, Tahseen A. Chowdhury, Naresh Kanumilli, Parijat De, Andrew H. Frankel, Ciara Doherty, Nicola Milne, Rosa M. Montero, Eirini Loudaki, Debasish Banerjee, Ritwika Mallik, Adnan Sharif, Sagen Zac-Varghese, Srikanth Bellary, Gabrielle Goldet, Ketan Dhatariya, Steve Bain Orcid Logo, Indranil Dasgupta

Kidney International Reports, Volume: 10, Issue: 10, Pages: 3318 - 3331

Swansea University Author: Steve Bain Orcid Logo

  • 70174.VOR.pdf

    PDF | Version of Record

    This is an open access article distributed under the terms of the Creative Commons CC-BY license.

    Download (1.32MB)

Check full text

DOI (Published version): 10.1016/j.ekir.2025.07.028

Abstract

A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hypergl...

Full description

Published in: Kidney International Reports
ISSN: 2468-0249
Published: Elsevier BV 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa70174
Abstract: A growing and significant number of people with diabetes develop chronic kidney disease (CKD) and diabetes related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated reduction in composite kidney endpoint events (significant decline in kidney function, need for kidney replacement therapy and kidney related death) and cardiovascular risk with sodium glucose co-transporter-2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and glucagon-like peptide 1 (GLP-1) receptor agonists. The Association of British Clinical Diabetologists and UK Kidney Association Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the pharmacological management of hyperglycaemia in adults with type 2 diabetes and CKD. This 2025 abbreviated updated guidance from a multidisciplinary group of healthcare professionals from primary and secondary care settings summarises the key recommendations and recent evidence that has implications for clinical practice for health care professionals who treat people with type 2 diabetes and CKD.
Item Description: Guidelines
College: Faculty of Medicine, Health and Life Sciences
Issue: 10
Start Page: 3318
End Page: 3331

Similar Items